Coronavirus disease (COVID-19) Associated mucormycosis (CAM)
Journal of Cellular Biotechnology
; 8(1):37-42, 2022.
Article
in English
| EMBASE | ID: covidwho-1987439
ABSTRACT
The currently prevalent COVID-19 infection, its line of treatment, resultant immunosuppression, and pre-existing comorbidities have made patients exposed to secondary infections including mucormycosis. Mucormycosis is a rare but in invasive fungal infection (IFI) due to several species of saprophytic fungi, occurring in patients with underlying co-morbidities which include diabetes mellitus, organ transplant, immunosuppressive corticosteroid therapy. The maxilla rarely undergoes necrosis due to its rich vascularity. Rare but not uncommon is the incidence of mucormycosis associated maxillary osteomyelitis occurring post COVID-19 infection. Fungal osteomyelitis is a life-threatening infection which may further spread from maxilla to the nose and paranasal sinuses within the orofacial region. It is an aggressive infection that needs to be addressed promptly to prevent fatal consequences.
adult; article; comorbidity; coronavirus disease 2019; corticosteroid therapy; diabetes mellitus; human; immunosuppressive treatment; incidence; maxilla; mucormycosis; mycosis; necrosis; nonhuman; nose; osteomyelitis; paranasal sinus; prevention; saprotroph; secondary infection; surgery; systemic mycosis; vascularization
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of Cellular Biotechnology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS